|Bid||1.15 x 3200|
|Ask||1.16 x 1000|
|Day's Range||1.15 - 1.17|
|52 Week Range||1.13 - 2.12|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 15, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.67|
Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that two-year follow-up data from its Phase I/II clinical study evaluating its allogeneic placenta-derived cell therapy product, PLX-PAD, for the treatment of muscle injury following hip replacement was published in the peer-reviewed Journal of Cachexia, Sarcopenia and Muscle. Pluristem also announced that its ongoing Phase III study in the treatment of muscle injury following hip fracture, which is underway in the U.S. and Israel, has been cleared to enroll additional patients in Denmark, Germany and the United Kingdom.
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported financial results for its fourth quarter and fiscal year ended June 30, 2018 and provided a corporate update. “The indications we are pursuing for our novel cell therapy products, PLX-PAD and PLX-R18, target underserved medical conditions for which there are no viable treatment options today,” stated Yaky Yanay, Co-Chief Executive Officer and President of Pluristem.
Pluristem Therapeutics Inc (NASDAQ:PSTI), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PSTIRead More...
HAIFA, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that Israel’s Ministry of Health has cleared the Company to commence patient recruitment in Israel for two ongoing pivotal Phase III trials of PLX-PAD cell therapy, one for the treatment of Critical Limb Ischemia (CLI) and another for the treatment of muscle injury following hip fracture surgery. Both trials have been accepted to accelerated approval pathways and have received a total of $16.7 million in grants from the European Union’s Horizon 2020 Program. “We are pleased to open clinical sites in Israel for both of our ongoing pivotal Phase III studies.
With hundreds of biotech stocks all assuring big prospects, building a portfolio of truly transformative medicine makers is a feat. B. Riley FBR said it's found two winners. The Analyst Analyst George ...
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that the Japan Patent Office has granted Pluristem a patent for the treatment of Acute Radiation Syndrome (ARS) and its impact on the gastrointestinal tract. The patent titled “Methods for Treating Radiation or Chemical Injury” relates to intramuscular (IM) administration of adherent stromal cells, cultured under three-dimensional culturing conditions, for mitigating intestinal damage in patients that have been exposed to radiation or chemotherapy.
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on PTLA sign up now at www.wallstequities.com/registration. WallStEquities.com revisits the Biotech space, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are the following equities: Pluristem Therapeutics Inc. (NASDAQ: PSTI), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Recro Pharma Inc. (NASDAQ: REPH), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN).
In this article, I will take a look at Pluristem Therapeutics Inc’s (NASDAQ:PSTI) most recent earnings update (31 March 2018) and compare these latest figures against its performance over theRead More...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Pluristem Therapeutics Inc. (NASDAQ: PSTI ) stock ...
Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent ...
Investors in Pluristem Therapeutics (PSTI) need to pay close attention to the stock based on moves in the options market lately.
Pluristem Therapeutics Inc’s (NASDAQ:PSTI): Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The US$156.33M market-cap posted a loss in its most recentRead More...
The Haifa, Israel-based company said it had a loss of 1 cent per share. The company's shares closed at $1.33. A year ago, they were trading at $1.32. _____ This story was generated by Automated Insights ...
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), which develops placenta-based cell therapy products, announced Monday that the FDA cleared an investigational new drug application for PLX-R18 cell therapy ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Allergan plc (NYSE: AGN ) stock was trading higher ...
Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event. Pluristem said it will start preparations to keep an emergency stock of PLX-R18 on hand for use in such events. Full approval of the drug will depend on the results of a Phase III clinical trial.